IDH1 and acute myeloid leukemia: However, with the development of novel therapeutics for AML, it would be reasonable to employ diagnostic and therapeutic strategies learned from the APL and IDH-mutated AML experiences followed by an iterative approach that incorporates emerging clinical findings [15,21].